Lupus erythematosus

This study tests whether training popular community leaders to share vaccine information can increase COVID-19 booster shots among Black individuals with rheumatic conditions like lupus. About 60 people will take part, including leaders and their social network members. The goal …

This phase 2 trial tests whether dapagliflozin, a drug already used for diabetes and chronic kidney disease, can slow kidney damage in people with lupus nephritis. Lupus nephritis is a serious complication of lupus that causes kidney inflammation and can lead to chronic kidney di…

This early-stage study tests a new drug called PIT565 in about 54 people with active lupus who have not gotten better with standard treatments. The main goal is to see if the drug is safe and how the body processes it. Participants will receive increasing doses of the drug and be…

This study is checking the long-term safety of a drug called dapirolizumab pegol for people with systemic lupus erythematosus (lupus). It involves 760 participants who have already completed earlier studies of the drug. Researchers will monitor side effects over time to see if th…

This early-stage trial tests an experimental drug called BI 3000202 in 16 adults with rare type 1 interferonopathies, such as Aicardi-Goutières syndrome. Participants take a low dose for 4 weeks, then a higher dose for 36 weeks. The main goal is to see if the drug is safe and how…

This study tests a drug called litifilimab for people with lupus-related skin disease that didn't get better with standard antimalarial pills. About 450 adults with active skin lesions will receive either the drug or a placebo every 4 weeks for 24 weeks, then everyone gets the dr…

This study tests a new medicine called anifrolumab, given as a shot under the skin, for adults with moderate-to-severe lupus. The goal is to see if it can better control disease activity compared to a placebo, when added to standard treatments. About 367 participants are involved…

This early-phase study tests a new treatment called NKX019 for people with lupus, an autoimmune disease. NKX019 uses specially engineered immune cells to target and calm overactive B cells. The main goal is to check safety in about 6 participants, while also looking for signs tha…

This early-stage trial tests clonal fetal mesenchymal stem cells (cfMSCs) in 100 people with severe immune-related disorders or tissue damage. The goal is to see if the cells are safe and can reduce symptoms. Participants have no other treatment options left.

This study looks at the long-term safety of a drug called litifilimab for people with active lupus. About 864 adults who finished earlier studies will continue taking the drug for up to 3 years, along with their usual treatments. The goal is to see how safe it is and how well it …

This study is tracking the long-term safety and effectiveness of the drug Saphnelo (anifrolumab) in over 1,600 people with systemic lupus erythematosus who haven't responded well to current treatments. Researchers are monitoring for side effects like serious infections, shingles,…

This study tests a new treatment called CHT105 for people with lupus nephritis that hasn't responded to standard therapies. CHT105 uses specially engineered immune cells from healthy donors to target and destroy the faulty immune cells causing kidney damage. Fourteen adults will …

This study tests an experimental drug called IMVT-1402 in people with lupus-related skin rashes (subacute or chronic cutaneous lupus) that haven't gotten better with standard treatments. About 56 participants will receive either the drug or a placebo for 12 weeks, then all get th…

This early-stage trial is testing a new treatment called KITE-363 for people with severe autoimmune diseases like lupus and scleroderma that haven't improved with standard treatments. KITE-363 is a type of cell therapy where a patient's own immune cells are modified in a lab to t…

This study follows 100 Polish adults with systemic lupus erythematosus (SLE) who are receiving anifrolumab as part of their routine care. Researchers will track changes in disease activity and overall response over time. The goal is to see how well the drug works outside of contr…

This early-stage study tests an injection called GC012F in 20 adults with refractory systemic lupus erythematosus (SLE) — a type of lupus that hasn't responded to standard treatments. The goal is to see if the therapy is safe and can reduce disease activity. Participants receive …

This early-stage study tests a new drug called RO7507062 in 70 people with systemic lupus erythematosus (SLE). The main goal is to check its safety and how the body processes it. Participants receive the drug as a shot under the skin, and the study will look for side effects and …

This study tests if a new 2mL auto-injector or pre-filled syringe delivers the same amount of the drug ianalumab into the body as the current 1mL syringe. About 155 adults with rheumatoid arthritis, Sjögren's disease, or lupus will receive the drug both ways to compare how much g…

This study tests a new drug called ianalumab for people with active systemic lupus erythematosus (SLE), a chronic autoimmune disease. About 436 participants receive either ianalumab or a placebo as a shot under the skin, once a month or once every three months, along with their u…

This early-phase trial is testing a new treatment called YTB323, a type of CAR T-cell therapy, in 21 adults with severe lupus that hasn't improved with standard treatments. The goal is to see if a single infusion is safe and can control the disease. Researchers will also measure …

This phase 3 study tests whether adding a monthly injection of ianalumab to standard lupus treatments helps control active disease better than placebo. About 288 people aged 12 and older with systemic lupus erythematosus (SLE) are taking part. The main goal is to see if ianalumab…

This early-phase study tests a new type of CAR-T cell therapy in 9 people with autoimmune diseases that have not responded well to standard treatments. The therapy uses specially engineered immune cells to target and attack faulty immune cells. The main goal is to check safety an…

This study planned to test a new cell therapy (CD19-BCMA CAR-T) for people with connective tissue diseases like lupus and rheumatoid arthritis. The goal was to see if it is safe and can control the disease. However, the study was withdrawn before enrolling any participants, so no…

This study aimed to test a new type of cell therapy (called CAR T-cells) in people with severe lupus or inflammatory myopathy that did not get better with standard treatments. The therapy uses donor cells to target and destroy faulty immune cells. However, the study was withdrawn…

This study follows 551 people with lupus who are starting anifrolumab for the first time. Researchers will track how well the drug controls disease activity, reduces flares, and improves quality of life over time. The goal is to see if the benefits seen in clinical trials hold up…

This study tests a non-invasive device that uses low-frequency electromagnetic fields to improve communication between immune cells. 120 adults with lupus, rheumatoid arthritis, or multiple sclerosis will receive either active or sham sessions three times a week for 12 weeks. The…

This phase 3 trial tests whether adding ianalumab (a biologic injection) to standard therapy helps control active lupus nephritis, a serious kidney complication of lupus. About 452 adults with active lupus nephritis are receiving either ianalumab every 4 or 12 weeks or a placebo,…

This phase 2 trial is testing an experimental drug called cenerimod in 15 Chinese adults with moderate-to-severe systemic lupus erythematosus (SLE). Participants take a 4 mg tablet daily for 12 months while continuing their usual lupus medications. The study focuses on safety, ho…

This phase 2 trial tests whether the drug afimetoran can safely control active systemic lupus erythematosus (SLE) better than a placebo. About 268 participants with lupus will receive either afimetoran or a placebo for 48 weeks, with an extension period allowing placebo users to …

This Phase 3 study tests whether obinutuzumab, an antibody drug given by IV, can better control active lupus compared to a placebo. About 303 adults with lupus who have high disease activity and specific antibodies are taking part. All participants continue their usual lupus medi…

This study tests the long-term safety of the drug litifilimab in adults with lupus skin disease (CLE) that didn't improve with standard antimalarial treatment. About 322 participants who completed a prior study will receive injections every 4 weeks for up to 2 years (or 5 years i…

This study looks at the long-term safety of cenerimod in adults with moderate-to-severe lupus. About 680 participants who were in a previous study will take cenerimod for up to 3 years, along with their usual lupus medications. Researchers will track side effects and see how well…

This phase 3 trial tests whether adding cenerimod, a daily pill, to standard lupus treatments can reduce symptoms in adults with moderate-to-severe systemic lupus erythematosus (SLE). About 470 participants will receive either cenerimod or a placebo for 12 months. Researchers wil…

This study tests anifrolumab, a biologic drug given as a shot, for adults with chronic or subacute lupus skin rashes that didn't get better with antimalarial drugs. About 306 participants will receive either anifrolumab or a placebo to see if the drug can reduce skin disease acti…

This early study tests whether tapinarof cream, already approved for psoriasis, can improve skin lesions in people with cutaneous lupus. Ten adults with active lupus lesions will apply the cream daily for 16 weeks. Researchers will measure changes in skin activity and study immun…

This phase 3 study tests whether upadacitinib (RINVOQ), a drug already used for arthritis, can safely control moderate-to-severe lupus. About 1,000 adults with lupus will take either the drug or a placebo daily for a year. Researchers will measure how well it reduces disease acti…

This study tests whether N-acetylcysteine (NAC), an antioxidant supplement, can help people with systemic lupus erythematosus (SLE). About 290 participants will first take NAC for 3 months to find a tolerable dose, then be randomly assigned to continue NAC or switch to a placebo …

This study looks at the long-term safety and effectiveness of enpatoran, an experimental drug for lupus. About 379 people who completed a previous 24-week study will take different doses of enpatoran or a placebo for up to 194 weeks. The goal is to see if the drug is safe and hel…

This Phase 2 study tests an experimental oral drug called ESK-001 in 408 adults with active systemic lupus erythematosus (SLE). Participants receive either ESK-001 or a placebo for 48 weeks to see if the drug can reduce disease activity. The goal is to find a new treatment option…

This Phase 3 study tests whether adding cenerimod to standard lupus treatments can better control moderate-to-severe lupus symptoms. About 451 adults will receive either cenerimod or a placebo for 12 months. The main goal is to see if more people improve on a lupus disease activi…

This Phase 2 trial tests whether the experimental drug SAR441344 can safely control disease activity in people with active systemic lupus erythematosus (SLE). About 109 adults aged 18–70 will receive either the drug or a placebo for 24 weeks. The main goal is to see if more peopl…

This Phase 2 trial is testing a new treatment called Descartes-08 for people with systemic lupus erythematosus (SLE). Descartes-08 uses a patient's own immune cells, modified to target a protein called BCMA, to try to control the disease. Only 6 participants with active lupus des…

This early-phase study tests a new treatment called Prula-cel for people with autoimmune diseases like lupus, scleroderma, and vasculitis. Prula-cel uses donor immune cells engineered to target and destroy faulty immune cells that attack the body. The goal is to find a safe dose …

This early-stage trial tests a new drug called SG301, given as an injection under the skin every two weeks, for systemic lupus erythematosus (SLE). The study first gives a single dose to healthy volunteers to check safety, then gives multiple doses to people with lupus. The main …

This study was designed to test a new treatment for people with autoimmune diseases like lupus, scleroderma, and myositis. It combined a specially engineered immune cell product (CLBR001) with a targeted antibody drug (SWI019), with or without a preparatory chemotherapy step. How…

This phase 3 study tests anifrolumab, an IV drug, against placebo in 359 adults with active lupus nephritis (kidney inflammation from lupus). The main goal is to see if more patients achieve complete kidney response, meaning better kidney function and less protein in urine. The t…

This phase 3 study tests litifilimab, an experimental drug, in 548 adults with active systemic lupus erythematosus (SLE) who are already on standard treatments. Participants receive either high or low doses of litifilimab or a placebo as injections every 4 weeks for 52 weeks. The…

This early-phase trial is testing a CAR-T cell therapy called RD06-04 in 12 people with active autoimmune diseases like lupus, scleroderma, and vasculitis. The treatment involves reprogramming a patient's own immune cells to target and destroy faulty B cells. The main goal is to …

This early-phase trial planned to test a one-time infusion of genetically modified immune cells (CAR-T cells) targeting CD19 in people with several autoimmune diseases, including lupus and multiple sclerosis. The goal was to see if it was safe and could reduce harmful antibodies.…

This early-stage study tests a new treatment for people with refractory systemic lupus erythematosus, a severe form of lupus that doesn't improve with standard medicines. The treatment uses the patient's own immune cells, modified to target and attack faulty immune cells that dri…

This early-stage trial tests a new treatment called RD06-04, a CAR-T cell therapy, in 12 people with moderate to severe lupus. The therapy aims to target and reset immune cells that attack the body. The main goal is to check safety and find the right dose, with a close watch for …

This study tests a new drug called litifilimab for people with active systemic lupus erythematosus (SLE), a chronic autoimmune disease. About 562 adults already on standard lupus treatments will receive either litifilimab or a placebo as a shot every 4 weeks for 52 weeks. The goa…

This study aimed to test whether the drug telitacicept could help people with moderate-to-severe lupus better than a placebo. It was designed for people aged 12 to 70 with active lupus symptoms. However, the trial was withdrawn before enrolling any participants, so no results are…

This early-stage study is testing a new treatment called CNTY-101 for people with severe autoimmune diseases like lupus, scleroderma, and inflammatory myopathies that haven't improved with standard therapies. CNTY-101 uses specially engineered immune cells to target and destroy f…

This study tests whether a pharmacist-led program can help people reduce their risk of heart disease. Over 1,000 adults with conditions like diabetes, high blood pressure, or obesity are taking part. Pharmacists use a step-by-step guide to assess risk and support lifestyle change…

This early-stage study tests a drug called felzartamab in 14 people with active lupus nephritis, a kidney condition caused by lupus. The drug is a lab-made antibody designed to lower harmful antibody buildup in the kidneys. The main goal is to check safety and how the drug works …

This study tests a new medicine called MIL62 in 120 adults with lupus, a chronic autoimmune disease. The goal is to see if MIL62 can reduce disease activity better than a placebo. Participants must have active lupus and be on a stable treatment plan. The study is not a cure but a…

This early-stage study tests a new treatment called AB-101 for people with lupus nephritis or other hard-to-treat lupus. AB-101 uses donated natural killer cells to boost the body's ability to fight the disease. The study aims to see if this approach is safe and can help patients…

This study tests whether the drug deucravacitinib can safely control symptoms in people with active moderate-to-severe lupus. About 513 participants will receive either the drug or a placebo. The goal is to see if the drug reduces lupus disease activity better than placebo.

This Phase 3 trial tests whether the oral drug deucravacitinib can safely control moderate to severe lupus better than a placebo. About 516 adults with active lupus are taking either the drug or a dummy pill for several months. The goal is to see if the drug reduces lupus symptom…

This early-stage study tests a therapy called SC291, made from donor immune cells, in 7 people with severe lupus or vasculitis that hasn't improved with standard treatments. The goal is to see if it is safe and tolerable, and to get a first look at whether it can control the dise…

This early-stage trial is testing a new treatment for people with severe lupus or scleroderma that hasn't responded to standard therapies. The treatment involves taking a patient's own immune cells, modifying them to target and destroy faulty immune cells, and giving them back al…

This early-phase trial is testing a personalized cell therapy called KYV-101 for people with lupus nephritis that hasn't responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and destroy faulty B cells that drive the disease. Only 2 p…

This study tests a weekly injection of belimumab, a drug that blocks a protein involved in lupus inflammation, in 25 children aged 5 to 17 with active lupus. The goal is to see if the drug reaches similar levels in the blood as in adults and to check its safety. If it works, it c…

This study offers expanded access to a stem cell treatment called HB-adMSCs for people with systemic lupus erythematosus (SLE). It is designed for adults 18 and older who have their own stem cells stored at Hope Biosciences. The goal is to check if the treatment is safe and helps…

This phase 3 trial tests whether adding sirolimus (rapamycin) to standard treatment helps control active lupus better than placebo. 146 adults with active lupus despite standard care will receive either sirolimus or placebo for 24 weeks, with an option to continue for another 24 …

This early-stage study tests a new drug called KK4277 in healthy volunteers and people with lupus (SLE or CLE). The main goal is to check safety and how the body processes the drug. It is too early to know if it works, but results will guide future research.

This early-stage study aimed to test a single infusion of CB-010, a CRISPR-edited CAR-T cell therapy made from donor cells, in people with severe lupus that did not respond to standard treatments. The trial was withdrawn before enrolling any participants, so no results are availa…

This study tests whether two blood pressure drugs, lisinopril and benazepril, can improve memory and concentration in people with lupus. Lupus is an autoimmune disease that can cause inflammation in the brain, leading to cognitive problems. The trial involves 36 adults with lupus…

This phase 2 trial tests deucravacitinib, an anti-inflammatory pill, against a placebo in 74 adults with active discoid or subacute cutaneous lupus — skin rashes caused by lupus. The main goal is to see if the drug reduces rash severity after 16 weeks. Participants must already b…

This study tests a new treatment for people with lupus or scleroderma that hasn't improved with standard care. The treatment uses specially engineered immune cells from a healthy donor (called universal CAR T-cells) to target and destroy faulty immune cells. The goal is to contro…

This study tests the Shingrix vaccine in over 2,000 adults with autoimmune rheumatic diseases like rheumatoid arthritis and lupus, who are at higher risk for shingles. Researchers will compare vaccinated patients to unvaccinated ones to see if the vaccine is safe and triggers a s…

This study tests an online program designed to help people with inflammatory arthritis remain employed. The program includes eLearning modules, group video sessions, and consultations with an occupational therapist and vocational counselor. About 528 participants from three Canad…

This study tests whether personalized coaching on physical activity and nutrition can reduce fatigue in people with lupus. 200 participants are split into two groups: one gets coaching on exercise and diet, the other gets general lupus education. The goal is to see if the coachin…

This study looks at whether clinical pilates exercises can reduce fatigue, pain, and emotional distress in women with systemic lupus erythematosus (SLE). Thirty women with low disease activity will do either pilates or home exercises for eight weeks. The goal is to see if this ge…

This study tests a personalized yoga coaching program for people with lupus who have chronic pain. Fifteen participants work with a coach to create a yoga practice that fits their needs and limits. The goal is to see if the program is feasible and if it helps reduce pain. It is a…

This study aims to better understand fatigue by comparing people who have felt tired for more than a month with those who are not fatigued. Researchers will use questionnaires, physical tests, and optional brain scans to identify different types of fatigue. The goal is to gather …

This study investigates whether people with systemic lupus erythematosus (SLE) show early signs of retinal damage before they notice any vision problems. Researchers will use advanced eye imaging and vision tests to compare lupus patients with healthy volunteers. The goal is to f…

This study follows 25 adults with inactive lupus to see if blood samples can predict when a flare will happen. Researchers will analyze genes and other molecules to find patterns linked to flare risk. The goal is to develop tools that help doctors personalize treatment and preven…

This study is a registry that will follow about 500 adults with lupus (SLE) in Kazakhstan to see how the disease behaves and how doctors treat it in everyday practice. Researchers will look at disease activity, organ damage, and which medications are used. No new treatments are b…

This study aims to create a tool that predicts which patients with inflammatory rheumatic diseases (like rheumatoid arthritis, vasculitis, or polymyalgia rheumatica) will develop serious side effects from long-term steroid use. Researchers will collect routine medical data—such a…

This study follows 510 people who had ACL knee reconstruction surgery, with or without an extra procedure called LET, about 10 years ago. Researchers want to see if adding LET increases the chance of developing knee osteoarthritis. Participants will get X-rays and answer question…

This registry enrolls up to 1,000 women aged 12–55 with rheumatic or autoimmune diseases who are pregnant or planning pregnancy. Researchers will collect data from medical records and patient surveys to study pregnancy outcomes, disease activity, and medication use. No experiment…

This study tests a program called HOP-STEP that helps doctors talk about pregnancy planning with women who have lupus. The goal is to make sure doctors document contraception use and pregnancy intentions during visits. The study involves 14 participants and is being tested at two…

This study checks how common swallowing difficulties (dysphagia) are in people with inflammatory rheumatic diseases like rheumatoid arthritis. Researchers used questionnaires to measure swallowing function, gut symptoms, and diet quality in 191 participants. The goal is to unders…

This study was designed to track pregnancies in women with rare autoimmune and systemic diseases to understand complications and improve care. It planned to enroll women with conditions like lupus, rheumatoid arthritis, and scleroderma. However, the study was withdrawn before any…

This study is building a large collection of blood samples from 3,000 people with rheumatoid arthritis. Researchers will use these samples to look for biomarkers that could help predict disease activity or treatment side effects. Participants must already be in a registry and sta…

This study looks back at the medical records of 180 people with lupus to compare two drugs: telitacicept and belimumab. The goal is to see which one works better at controlling the disease and has fewer side effects. Participants are not given any new treatment—the researchers si…

This study looks at 500 adults with lupus to see if certain immune markers can better predict who will develop heart disease. Participants give blood samples, have ultrasound scans of their neck arteries, and fill out diet and exercise questionnaires. The goal is to improve how d…

This study looks at whether stressful or traumatic life events increase the chance of developing fibromyalgia. Researchers will follow 534 adults—some with rheumatic diseases and some healthy—for one year, checking for new fibromyalgia cases. The goal is to better understand how …

This study looks at whether lupus flares cause swelling in the heart muscle. Researchers will use cardiac MRI to scan 40 lupus patients during a flare and again three months later. The goal is to better understand heart inflammation in lupus, not to test a new treatment.

This study looks at whether the shingles vaccine (HZ/su) is safe for pregnant women aged 18-49 with weakened immune systems. Researchers will track about 2,800 women to see if the vaccine raises the risk of birth defects or other problems in their babies. The goal is to provide r…

This study looks at whether helping people with inflammatory arthritis address social needs—like food, housing, or transportation—can reduce missed doctor visits. About 100 adults with conditions like rheumatoid arthritis or lupus who have missed appointments in the past year wil…

This study is the first time a new drug, GSK4347859, is being tested in humans. The goal is to check its safety and how it behaves in the body. It involves 65 healthy adults and is currently on hold. The drug is being developed for lupus, an autoimmune disease.

This study looks at immune cells from people with autoimmune diseases (like lupus), people with infections, and healthy volunteers. Researchers want to understand how these cells differ and what makes them attack the body in autoimmune conditions. The study involves blood and bon…

This study aims to understand how depression symptoms, like loss of interest, may make it harder for teens and young adults with lupus to keep up with their medical care. Researchers will also test a mobile health app designed to provide education and connect users to their care …

This study was designed to see if a new monitoring algorithm could detect early signs of ovarian damage in women and girls who had cancer treatment. Researchers planned to compare a group using the new algorithm with a group that received standard care. However, the study was wit…